SEC
BEAM icon

Seven Eight Capital’s Beam Therapeutics BEAM Stock Holding History

Seven Eight Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-9,747
Closed -$234K – 630
2023
Q3 		$234K Buy
+9,747
New +$261K 0.03% 544
2023
Q1 		– Sell
-5,774
Closed -$226K – 438
2022
Q4 		$226K Buy
+5,774
New +$259K 0.06% 353
2022
Q3 		– Sell
-5,908
Closed -$229K – 490
2022
Q2 		$229K Buy
+5,908
New +$235K 0.09% 308

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Seven Eight Capital's BEAM Position: Q4 2023 in Review

Seven Eight Capital sold out of Beam Therapeutics (BEAM) in Q4 2023, closing a stake of 9,747 shares — an estimated $234K sold.

Seven Eight Capital first reported a position in BEAM in Q2 2022 and held it in 3 quarters. The position peaked at $234K in Q3 2023. 185 funds tracked by Wall St. Rank hold BEAM as of Q4 2023.

  • Seven Eight Capital reported no remaining Beam Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Seven Eight Capital sold 9,747 Beam Therapeutics shares in Q4 2023, an estimated $234K.
  • Seven Eight Capital first reported a position in Beam Therapeutics in Q2 2022 and held it in 3 quarters.
  • Seven Eight Capital's Beam Therapeutics position peaked at $234K in Q3 2023.
  • 185 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2023.

Based on Seven Eight Capital's 13F filing for Q4 2023, filed 13 Feb 2024.